SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 93,515 shares of the company's stock, valued at approximately $2,504,000. SG Americas Securities LLC owned about 0.20% of Amphastar Pharmaceuticals at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. New York State Common Retirement Fund lifted its stake in Amphastar Pharmaceuticals by 86.4% in the 3rd quarter. New York State Common Retirement Fund now owns 90,169 shares of the company's stock valued at $2,403,000 after purchasing an additional 41,800 shares during the last quarter. Capital Fund Management S.A. acquired a new position in Amphastar Pharmaceuticals during the second quarter worth approximately $931,000. Rice Hall James & Associates LLC bought a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $3,447,000. SummerHaven Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $1,018,000. Finally, Quantbot Technologies LP lifted its position in shares of Amphastar Pharmaceuticals by 188.8% in the second quarter. Quantbot Technologies LP now owns 60,955 shares of the company's stock valued at $1,400,000 after buying an additional 39,846 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the company. Needham & Company LLC decreased their target price on Amphastar Pharmaceuticals from $34.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, February 27th. Barclays began coverage on Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They set an "equal weight" rating and a $30.00 price target for the company. Wells Fargo & Company reduced their price objective on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an "overweight" rating for the company in a research report on Friday, February 27th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $29.50.
Check Out Our Latest Report on AMPH
Amphastar Pharmaceuticals Price Performance
Amphastar Pharmaceuticals stock opened at $20.45 on Friday. The company has a market capitalization of $927.82 million, a price-to-earnings ratio of 10.07, a PEG ratio of 1.71 and a beta of 0.92. The company has a current ratio of 4.02, a quick ratio of 2.90 and a debt-to-equity ratio of 0.77. Amphastar Pharmaceuticals, Inc. has a 12 month low of $17.03 and a 12 month high of $31.26. The stock's 50 day moving average is $23.52 and its 200-day moving average is $25.24.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.24). Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. The firm had revenue of $183.11 million during the quarter, compared to the consensus estimate of $190.48 million. Equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.
About Amphastar Pharmaceuticals
(
Free Report)
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.
Read More
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A forward-looking investment report spotlighting the seven space companies best positioned to benefit from accelerating commercialization in 2026. It explores key industry trends, major growth catalysts, and the stocks shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
